Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PD-L1/ PD-1 inhibitor

- PMLiVE

Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC

Approximately half of all patients with early lung cancer experience cancer recurrence following surgery

- PMLiVE

Roche reveals promising phase 3 results for subcutaneous Ocrevus in progressive and relapsing MS

The chronic neurological condition affects more than 2.8 million people worldwide

- PMLiVE

Roche receives FDA breakthrough device designation for Alzheimer’s disease blood test

Around 55 million people globally are living with dementia, which is estimated to rise to 139 million by 2050

- PMLiVE

Roche’s Columvi combination shows promise as second-line DLBCL therapy

Approximately 160,000 people worldwide are diagnosed with DLBC every year

- PMLiVE

Roche and Exelis/Ipsen’s drug combination shows promise in phase 3 prostate cancer study

Around 299,000 new cases of prostate cancer will be diagnosed in the US in 2024

- PMLiVE

Roche’s Genentech and GenEdit enter autoimmune disease partnership worth up to $644m

The companies will develop nanoparticles to deliver genetic medicines for autoimmune diseases

- PMLiVE

New framework establishes two tests for use in clinical trials for Parkinson’s

The neurological condition currently affects around 145,000 people in the UK

- PMLiVE

Roche’s subcutaneous Tecentriq granted EC approval for multiple cancer types

The formulation reduces treatment time by around 80% compared to intravenous infusion

- PMLiVE

New antibiotic compound could potentially treat lethal hospital infections

Zosurabalpin successfully eliminated the multi-resistant A baumannii bacteria

- PMLiVE

Study programme to investigate blocking brain inflammation in Parkinson’s patients

If successful, the findings could lead to new medicines to treat the neurological disease

- PMLiVE

Roche shares positive late-stage results for inavolisib combination in advanced breast cancer

About 290,000 people in the US will be diagnosed with breast cancer in 2023

- PMLiVE

Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn

The company will gain access to a portfolio of incretin-based therapies for diabetes and obesity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links